Thyroid Cancer
Conditions
Brief summary
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Detailed description
1. Objective： To observe the difference between Thyogen® injection or Eltroxin® withdrawal on metabolic profile. 2. Background and method:： The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal. Inclusion ： Patient number: 500人 Inclusion criteria : 1. Patients with diagnosis of thyroid cancer。 2. Patients who need radioiodine therapy or scan。 Exclusion criteria: 1. Patients cannot cooperate with blood test.。 2. Patients cannot cooperate with radioiodine therapy。 Study design： Prospective, observational study。 Method： We will collect 20cc blood and 20 cc urine before and after radioiodine therapy during each visit (total 3 visits) and check lipid profiles, glucose profiles and inflammation markers. We will compare the difference between results of patients undergoing Thyrogen® injection and Eltroxin® withdrawal.
Interventions
RADIATIONradioiodine
Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
Sponsors
Taichung Veterans General Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with diagnosis of thyroid cancer。 2. Patients who need radioiodine therapy or scan。
Exclusion criteria
1. Patients cannot cooperate with blood test.。 2. Patients cannot cooperate with radioiodine therapy。
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Zung's Self-reported depression scale | 1 month | Depression symtpoms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brain-derived neurotrophic factor | 1 month | BDNF |
| orexin | 1 month | An associated factor for depression |
| Body composition | 1 months | Fat component percentage to lean mass percentage ratio |
| VCAM-1 | 1 months | adhesion molecules |
| CRP | 1 months | inflammation marker |
| Metabolic syndrome | 1 months | The number of conponents for metabolic syndrome |
| Insulin resistance | 1 month | HOMA-IR |
Countries
Taiwan
Outcome results
None listed